Jan 13, 2020 at 2:00 PM GMT Verona Pharma to Report 4 Week Phase 2b COPD Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy Listen to webcast Supporting Materials Positive Top-line Data in a 4 Week Phase 2b COPD Study with Nebulized Ensifentrine 361.3 KB
Nov 20, 2019 at 5:20 PM GMT Jefferies 2019 London Healthcare Conference Click here for webcast Supporting Materials View Presentation 1.9 MB
Nov 19, 2019 at 8:00 AM EST Stifel 2019 Healthcare Conference Presenter: Jan-Anders Karlsson, CEO Location New York, NY Supporting Materials Click here for the presentation 1.4 MB
Nov 18, 2019 Guggenheim Healthcare Talks Idea Forum | Neuro/Immunology Day Location New York, NY Supporting Materials Click here for the presentation 1.4 MB
Nov 5, 2019 at 8:00 AM EST Verona Pharma Third Quarter 2019 Financial Results and Conference Call To participate, please dial one of the following numbers and reference conference ID 6498479: 866-940-4574 for callers in the United States 0800 028 8438 for callers in the United Kingdom 0800 181 5287 for callers in Germany Click here for webcast
Sep 10, 2019 at 3:00 PM EDT 2019 H.C. Wainwright 21st Annual Global Investment Conference Location New York, NY Supporting Materials Click here for the presentation 1.1 MB
Aug 13, 2019 at 1:55 PM EDT 2019 Wedbush PacGrow Healthcare Conference Location New York, NY Supporting Materials Click here for Presentation 1 MB
Aug 6, 2019 at 8:00 AM EDT Verona Pharma Second Quarter 2019 Financial Results and Conference Call Click here for webcast
Aug 5, 2019 Ensifentrine (RPL554) Positive Data from 7-Day Phase 2 Clinical Trial in COPD Patients with Dry Powder Inhaler Formulation Supporting Materials Click here for Presentation 322.5 KB